8-K
filed February 8, 2023, 6:59 PM ET
ticker VNDA
CIK 0001347178
earnings
confidence high
sentiment negative
materiality 0.70
Vanda Q4/FY2022: revenue $64.5M/$254.4M, net income down; patent litigation continues
Vanda Pharmaceuticals Inc.
2022-FY EPS reported
$0.11
revenue$254,382,000
- Q4 total net product sales $64.5M (-5% YoY); FY2022 sales $254.4M (-5% YoY). Net income Q4 $6.9M ($0.12 diluted) vs $7.1M; FY net income $6.3M ($0.11) down from $33.2M ($0.58) in 2021.
- HETLIOZ sales Q4 $40.1M (-9% YoY) due to reimbursement challenges; Fanapt $24.4M (+2% YoY).
- Teva launched generic HETLIOZ at risk; appeal in patent litigation scheduled for March 14, 2023. New patent infringement lawsuits filed against Teva and Apotex.
- Plans to submit NDA for tradipitant (gastroparesis) and sNDA for Fanapt (bipolar I disorder) in H1 2023. Phase III motion sickness results expected mid-2023.
- No 2023 financial guidance provided due to uncertainties from HETLIOZ patent litigation.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Vanda Pharmaceuticals Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $254.4 million, net income $6.3 million, EPS $0.11.
- Period
- the fourth quarter and full year ended December 31, 2022
- Revenue
- $254.4 million
- Net income
- $6.3 million
- EPS
- $0.11
- Result
- reported results
Exact text from the filing
Total net product sales from HETLIOZ ® and Fanapt ® were $64.5 million in the fourth quarter of 2022
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Vanda Pharmaceuticals Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $254.4 million, net income $6.3 million, EPS $0.11.
- Period
- the fourth quarter and full year ended December 31, 2022
- Revenue
- $254.4 million
- Net income
- $6.3 million
- EPS
- $0.11
- Result
- reported results
Exact text from the filing
Total net product sales from HETLIOZ ® and Fanapt ® were $254.4 million for the full year 2022
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.